[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointenstinal-stromal-tumor-gist\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointenstinal-stromal-tumor-gist":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100633136","long-term-survivorship-challenges-of-advancedmetastatic-gist-patients-responding-to-tyrosine-kinase-inhibitor-treatment-an-observational-study-100633136",false,"NCT07522762","Long-term Survivorship Challenges of Advanced\u002FMetastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study","Long-term Survivorship Challenges of Advanced\u002FMetastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study (EORTC-1944)","Inclusion Criteria:\n\n* Age 18 years or older (no upper age limit);\n* Advanced or metastatic GIST, diagnosis of GIST must be histologically proven;\n* Treated with TKIs (eg. sunitinib, regorafenib, avapritinib, ripretinib) for at least 2 years; TKI treatment ongoing; interruptions up to 3 months are allowed;\n* Able to read and answer questionnaires;\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients receiving TKI in an adjuvant treatment setting.\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion the study.\n* Patients who are too ill (death is imminent), as determined by the referring health care professional.","ALL","18 Years",{"count":19,"type":20},330,"ESTIMATED","OBSERVATIONAL","Gastrointestinal stromal tumours (GISTs) are rare malignancies arising along the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) have substantially improved survival for patients with unresectable or metastatic GIST. As a result, an increasing number of patients live with advanced disease under chronic TKI therapy, highlighting the need to understand long-term survivorship, including health-related quality of life (HRQoL), treatment burden, and clinical outcomes.\n\nThis international, multicentre observational study includes two components: a retrospective cross-sectional study to evaluate the relevance and applicability of patient-reported outcome instruments, and a prospective cohort to document long-term clinical outcomes, HRQoL, treatment patterns, and survivorship challenges.\n\nParticipants will include adults with advanced or metastatic GIST who have received TKI therapy for at least 2 years. Data will be collected from medical records and through validated patient-reported outcome questionnaires at baseline and annually for up to 10 years. This study aims to provide insight into HRQoL problems, treatment discontinuation, coping strategies, and the impact of financial toxicity among long-term survivors of GIST.",[24],"Gastrointenstinal Stromal Tumor (GIST)",[26,27,28,29,30],"Gastrointestinal Stromal Tumor (GIST)","Tyrosine Kinase Inhibitor","Imatinib","Health-related quality of life","Metastatic disease","RECRUITING","2026-04-08",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":35},"2025-05-21",{"date":39,"type":20},"2037-05-21",{"name":41,"class":42},"The Netherlands Cancer Institute","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100624091","safety-of-robotic-surgery-for-gists-at-special-anatomic-sites-100624091","NCT07405125","Safety of Robotic Surgery for GISTs at Special Anatomic Sites","Safety of Robotic Surgery for Gastrointestinal Stromal Tumors at Special Anatomic Sites: A Multicenter, Prospective Clinical Study","Inclusion Criteria:\n\n* Aged 18 to 75 years, regardless of sex.\n* Diagnosis of GIST located at a special anatomic site confirmed preoperatively by endoscopy\u002Fendoscopic ultrasound, CT, or MRI.\n* Preoperative imaging suggests a tumor diameter between 2 cm and 5 cm.\n* No prior neoadjuvant therapy (e.g., imatinib) administered.\n* Expected survival period ≥ 6 months.\n* Preoperative assessment indicates feasibility for robotic surgery.\n* Preoperative examinations show no evidence of distant metastasis or direct invasion into adjacent organs.\n* Preoperative ECOG Performance Status score of 0 or 1.\n* Preoperative ASA Physical Status classification of I to III.\n* The subject has read and fully understood the patient information sheet and provided written informed consent.\n\nExclusion Criteria:\n\n* History of previous upper abdominal surgery (except laparoscopic cholecystectomy).\n* History of previous gastrectomy, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD).\n* Previous administration of neoadjuvant therapy (e.g., imatinib).\n* Presence of other active malignancies within the past 5 years or concurrently. (Note: Patients with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervical carcinoma in situ, breast carcinoma in situ, Stage I lung cancer, or Stage I colorectal cancer, may be enrolled.)\n* Requirement for concurrent surgery for other diseases.\n* Emergency surgery performed due to tumor-related complications (bleeding, obstruction, or perforation).\n* Arterial\u002Fvenous thrombotic events within 6 months prior to screening, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (excluding thrombosis related to prior chemotherapy venous catheters deemed resolved by the investigator), and pulmonary embolism.\n* Myocardial infarction within 6 months prior to surgery, or poorly controlled arrhythmia (including QTc interval ≥450 ms for males or ≥470 ms for females, calculated using Fridericia's formula).\n* Cardiac insufficiency classified as NYHA Class III-IV, or left ventricular ejection fraction (LVEF) \\\u003C50% on cardiac ultrasound.\n* Ventilatory dysfunction: FEV1 \\\u003C50% of predicted value.\n* Clinically symptomatic pleural or abdominal effusion requiring clinical intervention.\n* Human Immunodeficiency Virus (HIV) infection.\n* Active pulmonary tuberculosis.\n* History or presence of interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired pulmonary function that may interfere with the detection or management of suspected drug-related pulmonary toxicity.\n* Any active infection requiring systemic anti-infective therapy within 14 days prior to surgery; except for prophylactic antibiotic therapy (e.g., for urinary tract infection or chronic obstructive pulmonary disease).\n* Concurrent participation in another clinical trial involving surgical treatment.\n* History of alcohol abuse, drug abuse, or substance abuse. (Note: Patients who have ceased alcohol consumption may be enrolled.)\n* Patients deemed likely to be non-compliant with medical advice or medication regimens, or with incomplete data that may affect efficacy or safety assessment.\n* Pregnant or lactating female patients.\n* Any condition that may increase the risk associated with study participation, or other severe, acute, or chronic diseases, or any other situation that, in the investigator's judgment, makes the patient unsuitable for clinical study participation.","75 Years",{"count":53,"type":20},182,"INTERVENTIONAL",[56],"NA","This study is a prospective, multicenter, single-arm, phase II clinical trial. It plans to enroll 182 patients with localized gastric gastrointestinal stromal tumors (GISTs) at special anatomic sites. Eligible patients who meet the inclusion\u002Fexclusion criteria and provide written informed consent will undergo robotic radical surgery. Postoperative treatment will be determined jointly by the clinicians and patients based on actual clinical practice.",[24],"2026-02-08",{"date":61,"type":35},"2026-02-12",{"date":63,"type":35},"2026-02-01",{"date":65,"type":20},"2029-06-01",{"name":67,"class":42},"The First Affiliated Hospital with Nanjing Medical University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":78,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100613934","a-comprehensive-multinational-gist-registry-100613934","NCT07273045","A Comprehensive, Multinational GIST Registry","reGISTry - a Comprehensive, Multinational GIST Registry","reGISTTry","Inclusion Criteria:\n\n* Diagnosis of a gastrointestinal stromal tumor (GIST)\n* Verbal and written informed consent for participation in the study with planned prospective data collection\n* Physical and mental ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe neurological or psychological illness that impairs the ability to give informed consent",{"count":77,"type":20},1000,"20 Years","Patients diagnosed with a gastrointestinal stromal tumor (GIST), a rare type of tumor in the digestive tractparticipate in this scientific research study, known as a registry study, to help improve understanding and treatment of GIST.\n\nThis study collects medical information and biological samples-such as blood or tumor tissue-from patients. It does not involve new treatments, medications, or medical procedures. The patient's regular medical care will continue as usual, and participation will not require extra appointments or tests.\n\nThe study aims to learn more about how GIST behaves, especially in rare forms such as SDH-deficient or NF1-associated tumors. While targeted drugs are available for many patients, some tumors return or become resistant to treatment. By gathering data from many patients, researchers hope to better understand these challenges, identify risk factors for worse outcomes, and help design future studies and treatments-especially for rare types of GIST.\n\nIf the patient agrees to participate, information will be collected from their medical records, scans (such as CT or MRI), and doctor visits. They may be asked to complete optional questionnaires about their health and quality of life. If they consent, small blood samples (up to 50 ml) may be collected during routine check-ups. If surgery is needed, a small part of the tumor tissue may be stored for research. Other samples-such as saliva, stool, urine, or spinal fluid-may also be collected if they are taken during normal care, to study how bacteria in the body might affect the disease and treatment.\n\nParticipation is completely voluntary. The patient can choose to join or not, and can withdraw at any time without affecting their care or relationship with their doctor. Even if they do not agree to provide biological samples, they can still take part in the study by sharing medical data and scan results.",[24,81],"GIST - Gastrointestinal Stromal Tumor",[83,84,85,86,87],"GIST","KIT","SDH-Deficiency","NF1","register","NOT_YET_RECRUITING","2025-11-26",{"date":91,"type":35},"2025-12-09",{"date":93,"type":20},"2026-01-01",{"date":95,"type":20},"2056-01-01",{"name":97,"class":42},"Universität Duisburg-Essen"]